Drug Profile

BIOD 238

Alternative Names: BIOD-238; Ultra-rapid-acting insulin analogue - Albireo Pharma

Latest Information Update: 06 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biodel
Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Type 1 diabetes mellitus

Most Recent Events

02 Mar 2023 Albireo Pharma has been acquired by Ipsen
01 Dec 2015 Discontinued - Phase-I for Type-1 diabetes mellitus in Australia (SC)
21 Dec 2014 Biodel has patent protection for its ultra-rapid-acting insulin formulations in Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com